A situation we see at the front desk almost every week: a patient arrives holding two prescriptions from two different doctors — one says “FDG PET CT,” the other says “PSMA PET CT” — and the family wants to know which one is correct. Or an oncologist has asked for a FAPI scan after an FDG scan came back unclear, and the patient is quietly wondering whether the first scan was a waste of money.
None of these situations involve a mistake. They involve something that almost no one explains to patients: different PET scans are not better or worse versions of each other — they are different questions asked of your body. Once you understand what question each tracer asks, the choice between FDG, PSMA, FAPI, and DOTANOC stops being confusing and starts making obvious sense. That is exactly what this guide does, in plain language, with real decision scenarios at the end.
Quick answer: FDG PET shows glucose metabolism and is the general-purpose cancer scan for staging, response assessment, and recurrence in most cancers. PSMA PET targets a protein specific to prostate cancer cells and is the study of choice for prostate cancer staging and rising PSA. FAPI PET images the supportive tissue around tumours and shines where FDG struggles — certain stomach, pancreatic, liver, and mucinous cancers. DOTANOC/NOTANOC PET images somatostatin receptors and is the standard for neuroendocrine tumours. Your doctor picks the tracer that matches your cancer’s biology — and sometimes two scans together answer what one cannot.
The One Principle That Explains Everything
Every PET scan works the same way mechanically: a tracer is injected, it accumulates somewhere specific, and the scanner shows where. What differs is the homing mechanism of the tracer:
- FDG is a modified sugar. It accumulates wherever cells burn glucose fast — which most aggressive cancer cells do.
- PSMA is a molecule that binds Prostate-Specific Membrane Antigen — a protein prostate cancer cells display in large amounts.
- FAPI binds Fibroblast Activation Protein — found not on the cancer cells themselves but on the activated support cells (cancer-associated fibroblasts) that surround and feed many solid tumours.
- DOTANOC / NOTANOC bind somatostatin receptors — which neuroendocrine tumour cells carry in abundance.
So when your doctor switches from one scan to another, they are not upgrading the camera. They are changing the question — from “where is sugar being burned?” to “where is this specific protein being displayed?” Different cancers answer different questions loudly.
FDG PET CT: The Generalist
The whole-body FDG PET CT is the workhorse of oncology imaging worldwide, and for good reason — most common cancers (lung, lymphoma, colorectal, breast, head and neck, esophageal, melanoma and many more) consume glucose greedily, so they light up clearly.
FDG is typically the right first question when: staging a newly diagnosed FDG-avid cancer, checking how treatment is working, investigating suspected recurrence, or evaluating a cancer of unknown primary.
FDG’s known blind spots — and this is where the other tracers enter the story: some cancers burn little glucose (certain well-differentiated tumours, some mucinous cancers, classic prostate cancer, many neuroendocrine tumours), and some body regions have high natural glucose use (brain) or variable background (liver, stomach, inflamed tissue) that can hide disease. FDG also cannot tell inflammation from tumour with certainty, since both burn sugar. None of this makes FDG a weak test — it makes it a specific test, excellent at its own question.
Practical note: FDG needs 4–6 hours fasting and a blood-glucose check; diabetic patients get timing instructions at booking.
PSMA PET CT: The Prostate Specialist
Classic prostate cancer is famously quiet on FDG — it grows without the sugar-burning frenzy of other cancers. The 68Ga PSMA PET CT solves this by ignoring metabolism entirely and targeting a protein badge on the cancer cell surface.
PSMA is the study of choice when: staging newly diagnosed higher-risk prostate cancer, locating disease when PSA rises after surgery or radiation (even at low PSA values where CT and bone scans are usually blank), and assessing eligibility for Lu-177 PSMA therapy.
Worth knowing: “PSMA” is slightly misnamed — small amounts appear in other tissues and some non-prostatic tumours, which is one of several reading nuances an experienced nuclear medicine physician handles in the report. And in the rare aggressive prostate variants that lose PSMA expression, FDG can re-enter the picture — another example of tracers as complementary questions, not rivals.
Practical note: no fasting needed for the tracer itself.
FAPI PET CT: The Specialist for FDG’s Blind Spots
The 68Ga FAPI PET CT is the newest of the three and works on a genuinely different idea: instead of imaging cancer cells, it images the reactive scaffolding — activated fibroblasts — that many solid tumours build around themselves. Because normal healthy tissue contains very little activated FAP, the background is remarkably clean, and tumours stand out with high contrast even in “noisy” regions like the liver, stomach and peritoneum.
FAPI earns its place when: FDG was negative or equivocal despite strong clinical suspicion; the cancer type is known to be FDG-shy (certain gastric, pancreatic, hepatobiliary, lobular breast and mucinous tumours); peritoneal spread needs mapping before major surgery; or radiotherapy planning needs precise tumour delineation.
Honest caveat: FAPI is not a universal replacement for FDG. Fibrotic and healing tissues can also show FAP activity, and the tracer’s role is still being refined in ongoing research. It is a powerful complementary tool, ordered for specific reasons — which is exactly how your oncologist uses it.
Practical note: no fasting required for the tracer; scheduling is same-day-friendly at generator-equipped centres.
DOTANOC / NOTANOC PET CT: The Neuroendocrine Standard
Neuroendocrine tumours often grow slowly and burn little glucose — classic FDG blind-spot behaviour — but they display somatostatin receptors in abundance. The 68Ga DOTANOC and NOTANOC scans target exactly those receptors, making them the standard for NET detection, staging, and PRRT eligibility work-up. Interestingly, NETs are also where the two-scan strategy is most formalised: receptor PET plus FDG together reveal whether any part of the disease has transformed into an aggressive, receptor-poor form — the “flip-flop” pattern that changes treatment strategy. We cover that fully in our PRRT eligibility guide.
Side-by-Side: The Four Tracers at a Glance
| Feature | FDG PET | PSMA PET | FAPI PET | DOTANOC/NOTANOC PET |
|---|---|---|---|---|
| What it images | Glucose metabolism | PSMA protein on prostate cancer cells | Activated fibroblasts around tumours | Somatostatin receptors |
| Main role | General oncology staging, response, recurrence | Prostate cancer staging & rising PSA | FDG-shy cancers; gastric, pancreatic, hepatobiliary, peritoneal disease | Neuroendocrine tumours; PRRT work-up |
| Fasting for tracer | Yes, 4–6 hours + glucose check | No | No | No |
| Isotope | F-18 (110-min half-life) | Ga-68 (68-min half-life) | Ga-68 | Ga-68 |
| Therapy link | — | Lu-177 PSMA eligibility | FAP-targeted therapy (emerging) | Lu-177 PRRT eligibility |
| Key limitation | Inflammation mimics; misses low-glucose tumours | Prostate-focused; rare PSMA-negative variants | Fibrosis/healing can show uptake; evolving evidence | NET-focused; physiological organ uptake needs expert reading |
Real Scenarios: Which Scan Would Typically Be Chosen?
Scenario 1 — Newly diagnosed lung mass, staging needed. FDG PET CT. Lung cancers are strongly FDG-avid, and whole-body staging is FDG’s home ground.
Scenario 2 — PSA rising to 0.4 ng/mL two years after prostate surgery. PSMA PET CT. At low PSA levels, conventional imaging is usually blank; PSMA imaging is designed for precisely this question.
Scenario 3 — Strong suspicion of pancreatic or gastric cancer, but FDG scan inconclusive. FAPI PET CT. These tumour types are classic FDG underperformers and classic FAPI performers.
Scenario 4 — Flushing, diarrhoea, raised chromogranin A; NET suspected. DOTANOC or NOTANOC PET CT — the receptor study finds NETs that structural imaging and FDG routinely miss.
Scenario 5 — Known NET, PRRT being considered, but recent rapid progression. Receptor PET plus FDG — the flip-flop assessment that determines whether PRRT alone can control all disease sites.
Scenario 6 — Ovarian or colorectal cancer, surgeon needs to know peritoneal spread before operating. FAPI is increasingly valued here for its clean abdominal background, alongside or after conventional work-up — the treating surgeon’s call.
Scenario 7 — Two doctors, two different scan prescriptions. Usually both are right for the question each doctor is asking. Bring both prescriptions to the centre; the nuclear medicine physician can speak with your treating doctors and confirm the sequence — a two-minute call that prevents a wrong booking.
Can One Scan Replace Another? (The Question Behind the Question)
What patients often really mean is: “Can I do just one scan and save money?” The honest answer: when the tracers match the biology, yes — one right scan beats two wrong ones, and your doctor’s prescription already reflects that matching. But when your doctor orders two studies, it is because each answers something the other cannot — receptor status vs metabolic aggressiveness, prostate-specific disease vs a second suspected primary. Skipping one half of a deliberately paired work-up saves money on imaging and risks spending far more on a treatment aimed at the wrong target. For the cost side of individual studies, see our honest pricing guides — DOTANOC scan cost and what affects PET CT cost in Delhi — which explain what quotes should include and how to compare centres properly.
One Roof, All Four Questions — Why That Matters Practically
Because Ga-68 tracers decay in about an hour, they cannot be stored or shipped casually — centres without their own generator run PSMA, FAPI and DOTANOC only on external supply days. Neurad Diagnostic’s in-house 68Ga Gallium Generator programme supports the full Ga-68 menu — PSMA, DOTANOC, NOTANOC, FAPI, Exendin, Trivehexin — on a daily-availability basis, alongside FDG. For patients, that means paired studies (like the NET flip-flop work-up) can be scheduled within days of each other, on one platform, with one reporting team comparing them properly — Dr. Swagat Dash (MBBS, DNB – Nuclear Medicine) and Dr. Pradeep Chaurasiya (MBBS, DNB – Nuclear Medicine), with reports in 24 hours.
And if the safety side of any of these scans is on your mind — radiation doses, precautions at home afterwards, diabetes or pregnancy considerations — our plain-language guide to PET scan side effects and precautions covers all tracers honestly.
Frequently Asked Questions
1. Which PET scan is “best” for cancer?
There is no universal best — there is a best match for your cancer’s biology. FDG for most common FDG-avid cancers, PSMA for prostate, receptor PET for NETs, FAPI for specific FDG-shy situations. The prescription your specialist writes already encodes this matching.
2. Why did my FDG scan miss my cancer?
Some tumour types simply burn little glucose — certain gastric, pancreatic, lobular breast, mucinous and neuroendocrine cancers among them. The scan did not fail; the question did not fit. That is exactly why FAPI and receptor tracers exist.
3. Is FAPI PET better than FDG PET?
In specific cancers and regions — often yes for contrast and detection; overall — it is complementary, not a replacement. FAPI has its own caveats (fibrosis uptake, evolving evidence), and your oncologist orders it when those trade-offs favour it.
4. Can a PSMA scan be used for cancers other than prostate?
PSMA expression appears in some non-prostatic tumours and tissues, and research applications exist — but its established clinical role is prostate cancer. For other cancers, FDG, FAPI, or receptor tracers are usually the appropriate tools.
5. Why do FDG scans need fasting but PSMA/FAPI/DOTANOC scans don’t?
FDG competes with the glucose in your blood, so high sugar levels degrade the images. The Ga-68 tracers target proteins and receptors, not sugar pathways — so blood glucose does not interfere.
6. My doctor ordered two PET scans within two weeks. Is that safe?
When clinically indicated, yes — each study’s radiation exposure is modest and short-lived, and paired studies are a standard, deliberate strategy (the NET flip-flop work-up being the classic example). The information gained directly shapes major treatment decisions.
7. Do all four scans feel the same as a patient?
Essentially yes — an IV injection, a quiet uptake period, and 20–30 minutes on an open-ring scanner. The main practical differences are FDG’s fasting requirement and each tracer’s scheduling logistics.
8. Which scan does a “full body checkup” for cancer screening?
PET scans are diagnostic tools ordered on medical indication, not general screening tests for healthy people. If a specific concern exists, the right path is a doctor’s evaluation first — the appropriate scan, if any, follows from that.
9. Are all these scans available in Delhi on short notice?
FDG is widely available. The Ga-68 studies depend on tracer logistics — at generator-equipped centres like Neurad Diagnostic, PSMA, FAPI, DOTANOC and NOTANOC run on daily availability; call +91 8368225620 to confirm a date for your prescription.
10. What should I bring so the right scan gets done?
All prescriptions (even conflicting ones), biopsy and histopathology reports, tumour marker results, and previous imaging discs. If two doctors have advised different studies, the nuclear medicine team will coordinate with them before booking — that conversation costs nothing and prevents the wrong scan.
Conclusion: Match the Question to the Cancer
FDG, PSMA, FAPI and DOTANOC are not rungs on a ladder from ordinary to advanced — they are four different questions, each unbeatable on its own subject and mismatched outside it. Understanding that single idea dissolves nearly all the confusion patients feel when scan names change between prescriptions. Your specialist chooses the question; the centre’s job is to ask it well — fresh tracer, careful acquisition, expert reading, fast report.
If you are unsure which study your prescription calls for, or you are juggling advice from more than one doctor, call Neurad Diagnostic at +91 8368225620 — the nuclear medicine team will look at the actual prescriptions and clarify the sequence before you spend a rupee.
Neurad Diagnostic & Healthcare LLP
B-3, opp. Metro Pillar No. 233, Near Paschim Vihar West Metro Station, New Multan Nagar, Paschim Vihar, New Delhi – 110056
Phone: +91 8368225620 | +91 7011968879
Website: https://neuraddiagnostic.com
About the Medical Team
Dr. Swagat Dash — MBBS, DNB (Nuclear Medicine & PET-CT Imaging)
Over a decade of clinical expertise in nuclear medicine and advanced diagnostic PET-CT imaging.
Dr. Pradeep Chaurasiya — MBBS, DNB (Nuclear Medicine, Molecular Imaging)
Several years of expertise in PET-CT scans and nuclear medicine procedures.
Dr. Nishant Thapar — MBBS, MD Radiology (High-End Diagnostic Imaging, MRI, CT)
Extensive experience in diagnostic imaging with advanced radiological equipment.
Practicing at Neurad Diagnostic & Healthcare LLP, B-3, Near Paschim Vihar West Metro Station, New Multan Nagar, Paschim Vihar, New Delhi — 110056.
Clinically reviewed by the nuclear medicine team at Neurad Diagnostic & Healthcare LLP. This content is for general information only and is not a substitute for advice from your treating doctor. The choice of imaging study is always your treating specialist’s decision based on your complete clinical picture.